X-Chem Announces Phase 3 Milestone in Collaboration with Relay Therapeutics
WALTHAM, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- X-Chem, a global leader in innovative drug discovery services, announced the achievement of a milestone following Relay Therapeutics’ initiation of a Phase 3 clinical trial of a drug candidate developed from a compound identified through an X-Chem DNA-encoded chemical …
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Shufti تطلق حل مراقبة موثوقية المعاملات (Transaction Trust Monitoring) مزوّداً بـ AI Rule Builder الذي يحوّل سيناريوهات المخاطر المكتوبة بلغة بسيطة إلى قواعد تم التحقق منها واختبارها بأثر رجعي
- HiTHIUM Launches 4 MWh Sodium-Ion Energy Storage System with New 785 Ah Cell
- Canada could add $5.4B to GDP by processing more of its crops at home: EY
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →